In this episode of the podcast, Joe Moore sits down with Co-Founder and CEO of Numinus, Payton Nyquvest. Nyquvest tells the story of how ayahuasca became the cure for his chronic pain, and discusses how people so often fall into a box where their diagnosis becomes their identity and their lives become about symptom moderation and not getting to the root cause. He talks about how Numinus came about; how Health Canada’s Special Access Program could be huge towards more legalization; the importance of a safe container and community; and the need for a shift in how we view psychedelics and self work in general, from something we view as a last-ditch resort to something we treat more as regular preventative tune-ups or check-ins. Numinus is working with MAPS in their Phase 3 MDMA for PTSD study, and have just produced what may be the first legal psilocybin mushroom since the 1970s.

The post PT289 – Payton Nyquvest – Shifting the Mindset on Pain, Psychedelics, and Accessibility appeared first on Psychedelics Today.

Previous articlePsychedelic Bulletin: MDMA Fast-Tracked in UK; FDA Clears MindMed LSD Trial; More Psychedelic Drug Policy Reform Efforts Emerge
Next articlePsychedelic or Not: Of Mice, 5-HT2A Agonists, and Head Shakes